Literature DB >> 12525360

[Conservative management of malignant and borderline ovarian tumor].

Philippe Morice1, Sophie Camatte, Fabienne Wickart-Poque, Roman Rouzier, Patricia Pautier, Christophe Pomel, Catherine Lhommé, Christine Haie-Meder, Pierre Duvillard, Damienne Castaigne.   

Abstract

Conservative management of at least a part of one ovary and the uterus, in order to preserve fertility-potential, could be propose in most of patients with nonepithelial and borderline ovarian tumor. This conservative management could be performed even in patients with borderline ovarian tumor associated with noninvasive peritoneal implants (if complete resection of peritoneal disease). A removal of the preserved ovary after completion of the pregnancy(ies) is not necessary if patients agree to a careful follow-up procedure. In patient with epithelial ovarian cancer, conservative management could be performed only in case of young patients who desire to preserve fertility function with: unilateral tumor (stage IA), grade 1 (and 2?), who underwent an adequate staging surgery (including peritoneal washings, omentectomy, multiple peritoneal biopsies, uterine curettage and complete pelvic and paraaortic lymphadenectomy) and with a careful follow-up. A conservative management should not be performed in patients with tumor stage > IA and/or grade 3. Removal of preserved ovary should be performed after completion of pregnancy(ies) in order to reduce the risk of ovarian recurrence.

Entities:  

Mesh:

Year:  2002        PMID: 12525360

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  1 in total

1.  Outcomes of controlled ovarian hyperstimulation/in vitro fertilization for infertile patients with borderline ovarian tumor after conservative treatment.

Authors:  Chan Woo Park; Kwang Moon Yang; Hye Ok Kim; Sung Ran Hong; Tae Jin Kim; Kyung Taek Lim; Ki Heon Lee; Inn Soo Kang
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.